Loading...
A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model
INTRODUCTION: Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4(+) T cell...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4075150/ https://ncbi.nlm.nih.gov/pubmed/24987466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt256 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|